Get the Daily Brief
Latest Biotech News
J&J shells out $3.05B for Halda’s RIPTAC platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to gain the company's regulated induced proximity targeting chimera (RIPTAC) technology and lead candidate HLD-0915...
Merck buys Cidara for $9.2B — long-acting, strain-agnostic flu candidate in focus
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD388, a late-stage investigational long-acting, strain-agnostic antiviral designed to prevent symptomatic influenza in...
Roche invests in Freenome: $75M stake, ex-US commercialization deal
Roche and Freenome struck a multiyear collaboration that gives Roche exclusive rights to develop and commercialize kit-based versions of Freenome's blood-based cancer screening tests outside the...
Iambic raises $100M to scale AI drug discovery and bring candidates to clinic
Iambic closed an oversubscribed $100 million financing round to expand its AI platforms Enchant and NeuralPLexer and advance cancer drug candidates. The company says Enchant predicts clinical and...
DNAe targets 2027 launch for LiDia-SEQ: same-day bloodstream infection sequencing
UK molecular-diagnostics firm DNA Electronics presented data supporting its LiDia-SEQ rapid sequencing platform and announced plans to commercialize the cartridge-based instrument in 2027. Company...
Nordic Capital takes majority stake in Evosep to push proteomics into clinic
Private equity firm Nordic Capital acquired an 80% stake in Danish proteomics company Evosep to accelerate the firm's push into translational and clinical proteomics markets. CEO Morten Bern said...
TCR momentum: Captain T Cell funds pipeline and T-knife files CTA for solid tumors
Two developments underscore renewed investor and clinical momentum in T-cell receptor (TCR) therapies for solid tumors. Captain T Cell closed an equity financing round to advance its autologous...
J&J snaps up Halda for $3.05B — acquires RIPTAC 'hold-and-kill' platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD-0915 for...
Zanidatamab clears phase 3 barrier — two positive reads reshape HER2 GEA market
Zymeworks, in partnership with Jazz Pharmaceuticals and BeOne, reported positive topline results from the Phase 3 HERIZON‑GEA‑01 study: zanidatamab (Ziihera) plus chemotherapy improved...
Merck buys Cidara for $9.2B — aims at long‑acting, strain‑agnostic influenza prevention
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, a long‑acting, strain‑agnostic antiviral advancing in Phase III for influenza prevention in high‑risk populations. CD388...
Roche inks licensing pact with Freenome — $75M equity, ex‑US commercialization rights
Roche and Freenome signed a collaboration that could exceed $200 million, including a $75 million Roche equity investment, giving Roche exclusive ex‑US rights to develop distributed, kit‑based...
Iambic raises $100M — AI platform funding to move oncology candidates into clinic
Iambic closed an oversubscribed $100 million financing led by Abingworth and Alexandria Ventures to accelerate its multimodal AI drug discovery stack and advance cancer candidates toward the...
Hermes Biosciences raises $6M seed — automating extracellular vesicle isolation
Hermes Biosciences closed a $6 million seed round led by Genoa Ventures to commercialize a benchtop, hands‑off extracellular vesicle (EV) isolation system aimed at research and clinical labs. The...
Nvidia, Sheba, Mount Sinai team to build genomic LLM — noncoding DNA in focus
Nvidia, Sheba Medical Center’s ARC Innovation, and the Icahn School of Medicine at Mount Sinai launched a three‑year collaboration to develop a genomic foundation model (gFM) — a large language...
Fecal exfoliome (Foli‑seq) validated — new noninvasive window into gut immune state
Columbia University researchers introduced exfoliome sequencing (Foli‑seq), a targeted amplicon approach that profiles host RNAs from exfoliated gut cells in feces to monitor intestinal and immune...
Solid licenses AAV‑SLB101 to Andelyn — next‑gen capsid expands CDMO offerings
Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use AAV‑SLB101, Solid’s next‑generation capsid engineered for enhanced skeletal muscle and cardiac tropism with...
FDA tightens Elevidys label: myocarditis warnings and use limits
The FDA updated the prescribing information for Sarepta Therapeutics’ gene therapy Elevidys (for Duchenne muscular dystrophy), adding stronger myocarditis language and troponin‑I monitoring...
J&J pays $3.05B for Halda: buys RIPTAC 'hold-and-kill' platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 for...
Merck snaps up Cidara for $9.2B: targets long‑acting influenza prevention
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, a long‑acting, strain‑agnostic antiviral currently in Phase III (ANCHOR) for influenza prevention in high‑risk...
Zanidatamab beats trastuzumab: Phase III HERIZON‑GEA‑01 posts positive topline data
Partners Zymeworks, Jazz Pharmaceuticals and BeOne Medicines announced positive topline results from the Phase III HERIZON‑GEA‑01 trial: zanidatamab (Ziihera) plus chemotherapy improved...